BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 29389947)

  • 1. Whole exome sequencing in neurogenetic odysseys: An effective, cost- and time-saving diagnostic approach.
    Córdoba M; Rodriguez-Quiroga SA; Vega PA; Salinas V; Perez-Maturo J; Amartino H; Vásquez-Dusefante C; Medina N; González-Morón D; Kauffman MA
    PLoS One; 2018; 13(2):e0191228. PubMed ID: 29389947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating exome sequencing into a diagnostic pathway for epileptic encephalopathy: Evidence of clinical utility and cost effectiveness.
    Palmer EE; Schofield D; Shrestha R; Kandula T; Macintosh R; Lawson JA; Andrews I; Sampaio H; Johnson AM; Farrar MA; Cardamone M; Mowat D; Elakis G; Lo W; Zhu Y; Ying K; Morris P; Tao J; Dias KR; Buckley M; Dinger ME; Cowley MJ; Roscioli T; Kirk EP; Bye A; Sachdev RK
    Mol Genet Genomic Med; 2018 Mar; 6(2):186-199. PubMed ID: 29314763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cou Cou, flying fish and a whole exome please... lessons learned from genetic testing in Barbados.
    Scantlebury MH; Barrett KT; Jacinto S; Corbin DOC; Kerr M; Khan A
    Pan Afr Med J; 2021; 38():111. PubMed ID: 33912281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of whole-exome sequencing in progressive neurological disorders of children.
    Aaltio J; Hyttinen V; Kortelainen M; Frederix GWJ; Lönnqvist T; Suomalainen A; Isohanni P
    Eur J Paediatr Neurol; 2022 Jan; 36():30-36. PubMed ID: 34852981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of a Targeted Gene Panel for Identification of Genes Associated With Movement Disorders.
    Montaut S; Tranchant C; Drouot N; Rudolf G; Guissart C; Tarabeux J; Stemmelen T; Velt A; Fourrage C; Nitschké P; Gerard B; Mandel JL; Koenig M; Chelly J; Anheim M;
    JAMA Neurol; 2018 Oct; 75(10):1234-1245. PubMed ID: 29913018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability.
    Monroe GR; Frederix GW; Savelberg SM; de Vries TI; Duran KJ; van der Smagt JJ; Terhal PA; van Hasselt PM; Kroes HY; Verhoeven-Duif NM; Nijman IJ; Carbo EC; van Gassen KL; Knoers NV; Hövels AM; van Haelst MM; Visser G; van Haaften G
    Genet Med; 2016 Sep; 18(9):949-56. PubMed ID: 26845106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of whole-exome sequencing results in neurogenetic diseases.
    Balasar Ö; Başdemirci M
    J Hum Genet; 2023 Dec; 68(12):797-804. PubMed ID: 37524782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole Exome Sequencing in Pediatric Neurology Patients: Clinical Implications and Estimated Cost Analysis.
    Nolan D; Carlson M
    J Child Neurol; 2016 Jun; 31(7):887-94. PubMed ID: 26863999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of Whole Exome Sequencing for Diagnostic Odyssey Cases of an Individualized Medicine Clinic: The Mayo Clinic Experience.
    Lazaridis KN; Schahl KA; Cousin MA; Babovic-Vuksanovic D; Riegert-Johnson DL; Gavrilova RH; McAllister TM; Lindor NM; Abraham RS; Ackerman MJ; Pichurin PN; Deyle DR; Gavrilov DK; Hand JL; Klee EW; Stephens MC; Wick MJ; Atkinson EJ; Linden DR; Ferber MJ; Wieben ED; Farrugia G;
    Mayo Clin Proc; 2016 Mar; 91(3):297-307. PubMed ID: 26944241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and economics of targeted panel versus whole-exome sequencing in 878 patients with suspected primary immunodeficiency.
    Platt CD; Zaman F; Bainter W; Stafstrom K; Almutairi A; Reigle M; Weeks S; Geha RS; Chou J;
    J Allergy Clin Immunol; 2021 Feb; 147(2):723-726. PubMed ID: 32888943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinical utility study of exome sequencing versus conventional genetic testing in pediatric neurology.
    Vissers LELM; van Nimwegen KJM; Schieving JH; Kamsteeg EJ; Kleefstra T; Yntema HG; Pfundt R; van der Wilt GJ; Krabbenborg L; Brunner HG; van der Burg S; Grutters J; Veltman JA; Willemsen MAAP
    Genet Med; 2017 Sep; 19(9):1055-1063. PubMed ID: 28333917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consecutive medical exome analysis at a tertiary center: Diagnostic and health-economic outcomes.
    Kosaki R; Kubota M; Uehara T; Suzuki H; Takenouchi T; Kosaki K
    Am J Med Genet A; 2020 Jul; 182(7):1601-1607. PubMed ID: 32369273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic Impact and Cost-effectiveness of Whole-Exome Sequencing for Ambulant Children With Suspected Monogenic Conditions.
    Tan TY; Dillon OJ; Stark Z; Schofield D; Alam K; Shrestha R; Chong B; Phelan D; Brett GR; Creed E; Jarmolowicz A; Yap P; Walsh M; Downie L; Amor DJ; Savarirayan R; McGillivray G; Yeung A; Peters H; Robertson SJ; Robinson AJ; Macciocca I; Sadedin S; Bell K; Oshlack A; Georgeson P; Thorne N; Gaff C; White SM
    JAMA Pediatr; 2017 Sep; 171(9):855-862. PubMed ID: 28759686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positioning whole exome sequencing in the diagnostic pathway for rare disease to optimise utility: a protocol for an observational cohort study and an economic evaluation.
    Hayeems RZ; Bernier F; Boycott KM; Hartley T; Michaels-Igbokwe C; Marshall DA
    BMJ Open; 2022 Oct; 12(10):e061468. PubMed ID: 36216418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of whole-exome sequencing and copy number variation sequencing enables the diagnosis of rare neurological disorders.
    Jiao Q; Sun H; Zhang H; Wang R; Li S; Sun D; Yang XA; Jin Y
    Clin Genet; 2019 Aug; 96(2):140-150. PubMed ID: 30945278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proband-only medical exome sequencing as a cost-effective first-tier genetic diagnostic test for patients without prior molecular tests and clinical diagnosis in a developing country: the China experience.
    Hu X; Li N; Xu Y; Li G; Yu T; Yao RE; Fu L; Wang J; Yin L; Yin Y; Wang Y; Jin X; Wang X; Wang J; Shen Y
    Genet Med; 2018 Sep; 20(9):1045-1053. PubMed ID: 29095814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic Yield and Economic Implications of Whole-Exome Sequencing for ASD Diagnosis in Israel.
    Tal-Ben Ishay R; Shil A; Solomon S; Sadigurschi N; Abu-Kaf H; Meiri G; Flusser H; Michaelovski A; Dinstein I; Golan H; Davidovitch N; Menashe I
    Genes (Basel); 2021 Dec; 13(1):. PubMed ID: 35052376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temporal trends and yield of clinical diagnostic genetic testing in adult neurology.
    Guo MH; Bardakjian TM; Brzozowski MR; Scherer SS; Quinn C; Elman L; Orthmann-Murphy J; Tropea TF; Ellis CA; Gonzalez-Alegre P
    Am J Med Genet A; 2021 Oct; 185(10):2922-2928. PubMed ID: 34075706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does genomic sequencing early in the diagnostic trajectory make a difference? A follow-up study of clinical outcomes and cost-effectiveness.
    Stark Z; Schofield D; Martyn M; Rynehart L; Shrestha R; Alam K; Lunke S; Tan TY; Gaff CL; White SM
    Genet Med; 2019 Jan; 21(1):173-180. PubMed ID: 29765138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of the genetic basis of pediatric neurogenetic disorders at a tertiary referral hospital in Indonesia: Contribution of whole exome sequencing.
    Triono A; Iskandar K; Hadiyanto ML; Nugrahanto AP; Diantika K; Wijayanti VW; Herini ES
    PLoS One; 2023; 18(10):e0293113. PubMed ID: 37878632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.